Salbutamol: A Safety Meta-Analysis Overview Salbutamol, a widely used bronchospasm reliever, has been insufficiently scrutinized for potential risks. In a meta-analysis of 58 randomized controlled trials with 12,961 participants, the study unearthed a 34% incidence of total adverse events (AEs). Notably, severe AEs stood at 2%, and treatment discontinuation was 3%. Subgroup
Tag: chronic obstructive pulmonary disorder
